Evidence map›Paper›PMID 40085414›Full record

ArticleBreast cancer research and treatment2025

Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database.

Ling-Xiao Xie, Yang Liu, Yao-Guo Yang, Jing-Nan Wang, Yan-Qun Zhang, Tao Wang, Lu-Yang Bian, Hao Jiang, Xiao-Ming Su, Yong-Chun Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ling-Xiao Xie *Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Yang Liu *Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Yao-Guo YangDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Jing-Nan WangDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Yan-Qun ZhangDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Tao WangDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Lu-Yang BianDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Hao JiangDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Xiao-Ming SuDepartment of Radiation Oncology, the Ninth Medical Center of Chinese, PLA General Hospital, Anxiang North Road, Dewai, Chaoyang District, Beijing, 100101, China. smallcatsxm2022@163.com.
Yong-Chun ZhouDepartment of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China. zhouyongchun@bbmu.edu.cn.

Funding

Graduate Scientific Research and Innovation Project of Bengbu Medical University Byycxz23039National Natural Science Foundation of China 82002432Natural Science Foundation of Shandong Province ZR2020QH179Natural Science Research Project of Anhui Educational Committee 2023AH051978
6 · The paper itself

Abstract

purposeTo evaluate the role of Postoperative Radiotherapy (PORT) in HER2-positive metastatic breast cancer (MBC) in the context of targeted therapy and clarify the subgroups that may benefit from PORT.

methodsClinical data of female patients with HER2-positive MBC from the surveillance, epidemiology, and end results (SEER) database for the years 2016-2020 were collected according to established inclusion and exclusion criteria. The impact of PORT on patient survival was assessed, and subgroup analyses were performed to identify populations with potential benefits from PORT.

resultsA total of 541 patients from the SEER database were included in the analysis. The 3-year overall survival (OS) of the PORT group was significantly higher than that of the non-PORT group. (86.7% vs. 80.2%, P = 0.011). Multivariate analysis revealed that race and PORT were independent prognostic factors. Black patients and those who received PORT had longer overall survival (OS) (P < 0.05). Subgroup analysis suggested that PORT further improved OS in patients with mastectomy, advanced TN stage, high tumor grade, positive hormone receptor status, and multiple metastatic organs (P < 0.05).

conclusionPORT further improves the survival of HER2-positive MBC. Subgroup analysis suggests that patients with locally advanced stage (T3-4, N2-3), Grade III, HR-positive status, bone-and-visceral metastasis, and those who have undergone mastectomy benefit significantly.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedFemaleHumansMastectomyMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisRadiotherapy, AdjuvantSEER ProgramERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHER2-positiveMetastatic breast cancerPostoperative radiotherapySEER

Identifiers

PMID40085414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.